6th International Medical Congress of Armenia – CME Presentations

Plenary Sessions
John Bilezikian—Thyroid disorders
Viken Babikian—Stroke Care Advances in Armenia
Roger Hajjar—Gene and Cell Therapy for treatment in cardiology
Sharon Chekijian—Emergency Medicine and Disaster preparedness in Armenia
Nora Pashayan—Cancer screening program from principles to practice
Shant Shekherdimian—Primary Care Strengthening in Armenia: Challenges and Opportunities
Bagrat Alekyan—Cardiology
Iacopo Baussano—HPV/Vaccination/Cancer prevention
Haroutune—Armenian Outlook for Health Care in Armenia
Wayne Grody—Genomic Analysis of an Ancient Armenian Population from the Artsakh/Nagorno-Karabakh Region

Specialty Session Speakers
Rafi Avitsian—Enhanced Recovery after Craniotomy
Raffi Tachdjian—T2 Inflammation, a new specialty
Naira Baregamian—Parathyroidectomy for Uremic Hyperparathyroidism
Mikael Petrosyan—Training the Future Pediatric Surgeon
Dereck De Leon—Medical Education
David Hovsepian—Interventional Radiology: A vital part of modern healthcare
Garni Barkhoudarian—Minimally invasive and Keyhole Management of Brain and Skull-base Tumors
David Rogers—Anterior cervical spine surgery


Dr Bilezikian reports that he has received speaker honoraria from Amgen Inc., Eli Lilly and Company, and Novartis AG and consultant honoraria from Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Takeda Pharmaceutical USA and Warner Chilcott.

Dr Babikian has served on the Clinical Events Committee for Boston Scientific and the BAIM Institute for Clinical Research.

Dr Hajjar is founder and consultant to Askbio and Medera.

Dr Avitsian disclosed he is eligible for royalties with Integral Medical Inc.

Dr Tachdjian disclosed that he is a speaker and research asvisor for Speaker, Research advisor for Biocryst, Ionis, CSL Behring, Takeda, Pharvaris, Pharming. He is a research advisor for Kalvista. He is a speaker and advosor for Sanofi and Regeneron.

Dr Barkhoudarian discloses financial relationships as a consultant for CereVasc Inc and VTI Vascular Technology Inc.

All financial relationships with ineligible companies have been mitigated. None of the other speakers have disclosed financial relationships with ineligible companies.